Lexicon Pharma (LXRX) Tops Q2 EPS by 11c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.55 +11.35%
Revenue Growth %: -86.1%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
CGEH, NAKA, APOG, More
Revenue Growth %: -86.1%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.33), $0.11 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $12.1 million versus the consensus estimate of $18.34 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
- Micron Technology (MU) Tops Q3 EPS by $4.62, Guidance Beats
- KeyBanc lowers Nike rating to Sector Weight on near-term uncertainty
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
